+ FCL (n = 10) was significantly lower than in 3q27 − FCL cases (P = 0.035). Finally, this study showed that BCL-6 expression in lymphoma is largely independent of chromosome 3q27 rearrangement and is more related to the histological subtype. Clinical implication and alternative deregulation pathways of BCL-6 expression remain to be determined.
Introduction
The BCL-6 gene, located on chromosome 3q27 encodes a zinc-finger transcriptional repressor. 1, 2 BCL-6 protein expression is required for germinal center (GC) formation and is highly regulated during B cell differentiation, expressed in centrocytes and centroblasts and conversely down-regulated in pre-or post-GC cells. [3] [4] [5] Several target genes down-regulated by BCL-6 have been identified, which are implicated in B cell terminal differentiation (Blimp-1, STAT3), Th2 immunity and inflammatory response (IP-10, MIP␣), cell cycle control (p27, cyclin D2) or apoptosis (BCL-XL).
6-8 BCL-6 translocations, identified by cytogenetic or Southern blot analysis, can occur in a broad spectrum of B cell lymphomas. The gene is rearranged in about 30% of diffuse large B cell lymphoma (DLBCL) and in 8 to 15% of follicle center lymphomas (FCL), [9] [10] [11] but also less frequently in other lymphoma subtypes including nodal and extra-nodal marginal zone lymphoma (MZL), 12, 13 or lymphocyte predominant Hodgkin's disease (HD). 14 Immunoglobulin gene (Ig) loci are the most frequently involved partners, 15 but several other non-Ig gene partners have also been characterized, including the small G protein TTF (4p11), 16 the B cell transcriptional coactivator BOB1 (11q23), 17 the Ikaros gene (7p12), 18 or the splicing factor SRP20 (6p21). 19 In almost all cases, breakpoints are located in the 5Ј extremity of the first intron and the rearrangement conducts to substitute BCL-6 regulatory regions with those of the partner, keeping the coding region intact in all cases. 20, 21 As a consequence, the promoter substitution by translocated elements results in constitutive expression of BCL-6 and may contribute to lymphomagenesis. 21, 22 However, several observations have suggested that the regulation of the gene in lymphomas could be more complex. For example, up-regulation of BCL-6 protein expression is observed in a wide spectrum of non-Hodgkin lymphomas (NHL), including T cell NHL, without evidence of translocation of the gene. [23] [24] [25] Moreover, deletions or point mutations of the first BCL-6 intron, occurring independently or simultaneously with BCL-6 rearrangement, represent the most frequent genetic changes in lymphoma cells and normal GC B cells. [26] [27] [28] They usually implicate identified regulatory elements 2, 29 and may up-or down-regulate expression of the gene. [30] [31] [32] The aim of the present study was to compare the level of BCL-6 mRNA expression by a real-time quantitative reverse transcription-polymerase chain reaction (Q RT-PCR) using TaqMan technology in node biopsies of FCL and DLBCL characterized by the presence or absence of BCL-6 translocation. We also evaluated the BCL-6 mRNA expression in different lymphoma subtypes in which BCL-6 rearrangement is usually not observed.
Materials and methods

Patients and cell lines
One hundred and five lymph node biopsies surgically removed from patients at the Centre Henri Becquerel from January 1994 to October 2001, were selected according to pathological and cytogenetic criteria.
Histological diagnosis was performed according to criteria of the REAL classification 33 by three pathologists. For FCL cases, 26 samples (three relapses) were studied, including 10 cases selected for the presence of a 3q27 rearrangement. For DLBCL cases, 20 samples (including three BCL-6 mRNA expression in different lymphoma subtypes F Jardin et al 2319 relapses) were selected for the presence of a 3q27 translocation assessed by conventional cytogenetic analysis (see below) and compared with 14 cases (three relapses) without evidence of 3q27 rearrangement. One case without cytogenetic data was included for the comparison with the other lymphoma subtypes.
The other histological subtypes of lymphoma were randomly chosen regardless of the 3q27 status and included seven classical Hodgkin's disease (HD), six chronic lymphocytic leukemia (CLL), seven nodal marginal zone lymphomas (MZL), six mantle cell lymphomas (MCL) and five peripheral T cell lymphomas (PTCL).
Additionally, mRNA obtained from two acute pre-B leukemia circulating cells, six nodal carcinoma metastasis (NM) and eight reactive hyperplasia (RH) were included in the study.
Two lymphoma cell lines were also analyzed: the VAL cell line was obtained from a DLBCL case characterized by a complex t(8;14;18)(q24;q32;q21) and a t(3;4)(q27;p11) translocation associated with an extensive deletion of the BCL-6 first intron. 34 The REC cell line was derived from a MCL case with a t(11;14) but lacking BCL-6 rearrangement (unpublished data).
Cytogenetic and Southern blot analysis in DLCBL and FCL
A complete karyotype analysis using conventional cytogenetic methods, as previously described, 15 was available in 34/35 DLBCL cases and in all FCL cases. Rearrangement of BCL-6 gene was subsequently studied by a Southern blot method in FCL and DLBCL cases with a 3q27 rearrangement, using the genomic probe F372, which overlaps the major translocation cluster (MTC), as previously reported. 9 
RNA extraction
Total RNA was extracted from lymph nodes biopsies by the single phase phenol guanididium method (RNA NOW, Biogentex, TX, USA). The integrity of the RNA samples was assessed by the visualization of 18S and 28S RNA bands after electrophoresis in agarose gels and ethidium bromide staining.
cDNA synthesis
Total RNA (1 g) was used for reverse transcription (RT), following dentaturation for 10 min at 65°C, in a total volume of 20 l containing 4 l of 5 × RT buffer (3 mM MgCl 2 , 75 mM KCl, 50 mM Tris-HCl, pH 8.3), 20 U of RNAsin ribonuclease inhibitor (Promega, Madison, WI, USA), 200 U MMLV reverse transcriptase (Promega), 200 pM of random hexamers (Amersham Pharmacia, Amersham, UK), and 20 mM dithiothreitol. Samples were incubated at 37°C for 90 min and the reverse transcription was inactivated by heating at 65°C for 10 min and cooling at 5°C for 5 min. Sterile water was added to dilute the final volume to 100 l.
Primers and probes
Primers and probes were chosen with the assistance of the computer program Primer Express (Table 1 ) (Perkin-Elmer Leukemia Applied Biosystems, Foster City, CA, USA). To avoid DNA amplification, primers were designed to cross an exonintron boundary.
As exon 1A and exon 1B of BCL-6 gene undergo alternative splicing, BCL-6 primers were located on exon 2 and 3.
The porphobilinogen deaminase gene (PBGD) was used to normalize BCL-6 expression. PBGD is transcribed as two distinct mRNAs: a housekeeping transcript expressed in all tissues and a tissue-specific transcript expressed during erythroid differentiation. 34 Because only the housekeeping mRNA contains the first exon, the forward primer was located in the first exon to avoid amplification of the specific erythroid transcript.
BCL-6 and PBGD probes were labeled with 6-carboxyfluorescein phosphoramidite (FAM) or VIC dye respectively at the 5Ј end and with 6-carboxy-tetramethyl-rhodamine (TAMRA) as quencher at the 3Ј end.
Real-time Q-RT-PCR assay
BCL-6 mRNA and PBGD mRNA expression were measured separately by real time quantitative RT-PCR using TaqMan technology (ABI PRISM 7700, PE Applied Biosystems). For each PCR, a master mix was prepared with 2 × TaqMan buffer; 25 mM MgCl 2 ; 200 mM dNTP; 400 mM dUTP; and 1.25 U of ampliTaq Gold DNA polymerase (Perkin Elmer Applied Biosystems). PCR was carried out with 900 nM of each primers and 150 nM of appropriate probe. 10 l of each diluted cDNA was added to 40 l of the PCR Master Mix. Thermal cycling conditions comprised an initial UNG incubation at 50°C for 2 min, Ampli taq Gold activation at 95°C for 10 min, 50 cycles of denaturation at 95°C for 15 s, and annealing/extension at 65°C for 1 min. Each run included the five points of the calibration curve for PBGD and BCL-6, the calibrator sample, the experimental samples, and a nontemplate control, all in duplicate.
Standard curves and quantification
Standard curves were established for BCL-6 and PBGD RNA with four-fold serial dilutions of total RNA from a human reactive lymph node in an irrelevant bacterial RNA (E. coli). Human reactive lymph nodes RNA (1000, 250, 62.5, 15.6 and 3.9 ng) was used to establish a standard curve. Threshold cycle (C T , the fractional cycle number at which the generated fluorescence of the probe passes a fixed threshold above baseline) was defined as 10 times the standard deviation of the baseline and was used to determine the quantity (Q) of BCL-6 and PBGD mRNA. For each sample, amount of BCL-6 mRNA was referenced to PBGD expression and arbitrarily calibrated to a low BCL-6/PBGD ratio determined in each assay for a reference acute B cell leukemia sample. BCL-6 relative expression was calculated as follows: BCL-6 expression = (Q BCL-6/Q PBGD) sample /(Q BCL-6/Q PBGD) calibrator .
Reproducibility
Variability was assessed by RNA obtained from the VAL cell line (1000, 500, 250, 125, 62.5, 31.25 and 15.6 ng). Each quantity was tested (×6) for PBGD and BCL-6 mRNA and the obtained C T were compared to estimate the intra-run variability. To assess the inter-run reproducibility we carried out four independent quantification assays for the seven mRNA amounts. For the intra-and inter-run assay, we calculated the coefficient of variability for BCL-6 and PBGD.
Statistical analysis
Levels of BCL-6 relative expression were compared with the histological subtype and BCL-6 rearrangement status using the non-parametric Mann-Whitney test.
Results
Methodology
We carried out a method based on real-time analysis of PCR and TaqMan technology, which represents a well-known valuable tool in characterizing minimal residual disease but has also been successfully applied to study gene expression in a variety of tumoral tissues. [36] [37] [38] Results obtained by the study of two cell lines, one obtained from a DLBCL with BCL-6 rearrangement and one obtained from a MCL, a proliferation well known for its absence of BCL-6 expression, validate the relevance of the method (Table 3) . PBGD gene expression was constant in the two cell lines despite their wide histological and cytogenetic divergence, confirming its use as a valuable control and reference gene.
Using total RNA extracted from a non-tumoral reactive lymph node and serially diluted, we observed a strong linear relationship between the C T and the log of the starting RNA quantity for BCL-6 and PBGD genes (Figure 1) .
The efficiency of the reaction (E), calculated by the formula E = 10 1/m − 1, where m is the slope of the standard curve, ranged above 90% for both genes.
Reproducibility
The variability of the method was assessed in a wide range of amounts of RNA (1000 to 15.6 ng) obtained from the VAL cell line using several repeated measurements in the same run (intra-run reproducibility) or in different runs performed on different days (inter-run variability).
Results for BCL-6 and PBGD are summarized in Table 2 and showed high reproducibility of the method. The mean CV of the BCL-6 PCR for intra-and inter-run was respectively 0.50% and 0.89% and we did not observe a difference of more than 0.5 log between two measured C T .
Figure 1
BCL-6 standard curve by real-time RT-PCR. Curves were established for BCL-6 and internal control with four-fold serial dilutions of total RNA from a human reactive lymph node (black dots). Quantification of the BCL-6 mRNA amount of unknown samples (red dots) is deduced from the linear relationship obtained between threshold cycle of PCR to obtain a significant fluorescence and the starting quantity of mRNA.
BCL-6 relative expression in different lymphoma subtypes
The results of 105 lymph nodes biopsies are summarized in Table 3 . FCL cases showed the highest level of expression. The mean level was 9.2 and is significantly higher than those of the other lymphomas tested (P Ͻ 0.001), as well as RH (P = 0.04) and NM (P = 0.004 ) cases.
In DLBCL, the level of expression was lower and more homogeneous, with a mean of 2.5. It remains significantly higher than those observed in MCL (P = 0.03) and CLL (P = 0.04) cases, whether no significant difference was observed with MZL (P = 0.10), PTCL (P = 0.19), RH (P = 0.19) or HD cases. The lowest level of expression was observed in the MCL and the CLL group, with a similar mean of 1.2. 
Association of 3q27 rearrangement in FCL with BCL-6 expression
A chromosome 3q27 rearrangement was observed in 10/26 cases of FCL including five cases with t(3;14)(q27;q32), two cases with t(2;3)(q27;p12) and three cases with an unidentified partner (add 3q27) by conventional cytogenetics. Subsequent analysis by Southern blotting with the F372 probe confirmed implication of the MTC in six of nine cases (67%). Negative cases had a derivative 3q27 chromosome (two cases) and a t(3;11)(q27;q23). We observed that the 3q27 translocated group had a sigLeukemia nificantly lower level of expression as compared to FCL without 3q27 rearrangement (P = 0.03) (Figure 2a) . However, BCL-6 mRNA expression in 3q27+ FCL cases remains higher than in DLBCL cases with or without 3q27 rearrangement (P = 0.01 and 0.003, respectively). FCL with the hallmark t(14;18) translocation expressed BCL-6 mRNA more than those without the translocation (P = 0.04).
Using the Berard method of grading, we identified eight grade 3 FCL (including one case with a t(14;18) translocation and five cases with a 3q27 rearrangement) and observed a significantly lower level of BCL-6 expression comparatively to grade 1-2 cases (P Ͻ 0.001). BCL-6 expressions in grade 3 FCL and in DLBCL were comparable with means of 3.14 and 2.53, respectively (Table 3) .
Association of 3q27 rearrangement in DLBCL with BCL-6 expression
Chromosome 3q27 rearrangements were observed by standard cytogenetic analysis in 20/34 studied patients. Seventeen of 20 rearranged cases were analyzed by Southern blot using the F372 probe, which confirmed implication of the MTC in 13/17 (75%) of cases. Among the Southern blot negative cases, two had a derivative 3q27 chromosome (add3q27), one a t(3;14)(q27;q32) and one a t(3;22)(q27;q11).The three patients without Southern blot showed a t(3;14)(q27;q32) in two cases and a t(3;22)(q27;q11) in one case.
Although the highest level of BCL-6 expression was observed in a lymphoma with a t(3,14)(q27;q32), we did not find a significant difference between the two groups defined by absence or presence of 3q27 rearrangement (Figure 2b) . We then compared BCL-6 expression with regards to the rearranged partner chromosome. In 12 cases, the BCL-6 partner was located on 14q32, and most likely implicated the IgH locus. In one case, chromosome 22q11 was involved, where the chain genes are located. BCL-6 expression of these cases was compared to a group constituted by lymphomas implicating non-Ig partners and located on chromosome 5p13, 6p21, 11q23 or unidentified partners (add3q27). We did not observe a significant difference between the Ig or the non-Ig translocated partner group (P = 0.9) ( Table 3) .
Discussion
The aim of the present study was to establish a reproducible and robust quantitative RT-PCR method to evaluate expression of the BCL-6 gene, and utilize the assay to assess this expression, among different histological lymphoma subtypes, correlating levels with chromosome 3q27 rearrangement. Recently, a study by Lossos and colleagues 37 evaluated BCL-6 gene expression using this same technology with different primers and GAPDH gene as an endogenous control. Despite these differences, we observed similar results regarding the mean level of BCL-6 expression in FCL, DLBCL or MCL.
Interestingly, we found that BCL-6 expression appeared closely associated with the lymphoma subtype. FCL cases expressed the highest level of BCL-6 mRNA, compared to the other lymphomas, whereas CLL or MCL cases expressed the lowest level. In PTCL, BCL-6 expression appeared low, but was comparable for one case to that observed in FCL and supports the finding that about one third of PTCL cases expresses BCL-6 protein and that BCL-6 expression could be associated in some cases with a follicular growth pattern. [23] [24] [25] In HD, BCL-6 expression is heterogeneous, and trended to be lower than in DLBCL, reflecting most likely in the subtype we analyzed, the expression of reactive cells rather than the tumoral scattered Reed-Sternberg cells, usually known to lack BCL-6 protein expression. 39, 40 For MZL cases, we also observed a low, but heterogeneous expression, supporting the fact that MZL do not usually express BCL-6 protein. 39, 40 Finally our results are in agreement with those previously observed using a semiquantitative immunohistological method, [39] [40] [41] [42] but are also supported by those obtained using DNA micro-arrays, 29, 33 suggesting that post transcriptional modification, described in normal GC B cells 3 is not a general mechanism of regulation implicated in lymphomas.
Our data show clearly that BCL-6 is more frequently expressed in FCL, a subtype of lymphoma which usually lacks BCL-6 rearrangement. This result was particularly evident in cases with t(14;18) translocation, whereas FCL with a 3q27 translocation had a significantly lower expression. However, BCL-6 expression in FCL with 3q27 translocation remains higher than in other lymphoma subtypes. These results illustrate the fact that up-regulation of BCL-6 is more closely associated with the development stage of the tumor than related to the translocation of the gene. These results also support the hypothesis that FCL with 3q27 translocation could represent a distinct subtype of lymphoma issued from the GC. 67 The role of BCL-6 in oncogenesis of FCL remains undetermined. The fact that we found a higher level of expression in FCL than in RH most likely reflected, in the subtype we analyzed, the tissue heterogeneity observed in the RH cases, rather than a direct oncogenic effect of BCL-6. Comparison of gene expression between normal nodes and FCL by micro-array is consistent with this hypothesis as BCL-6 did not appear upregulated during the malignant transformation, conversely to several others genes, such as BCL-2. 44 Interestingly, we observed a significant lower level of BCL-6 expression in grade 3 FCL, than in grade 1-2 (P Ͻ 0.001), but similar to those observed in DLBCL cases, suggesting that these lymphomas most likely represent, as clinical, histopathological and cytogenetic studies have previously highlighted, a different subset of FCL. 45, 46 This result also raises the possibility that a loss of BCL-6 expression could participate in a more aggressive disease, as previously reported in some transformed FCL. 47 We studied 20 DLBCL with 3q27 rearrangement in which subsequent Southern blot analysis confirmed involvement of the MTC in 75% of cases and did not find any significant difference in BCL-6 expression between groups of DLBCL with or without 3q27 translocations. Negative cases by Southern blot analysis most likely are related to the presence of alternate breakpoints, 48 rather than implicating an unidentified gene in 3q27 chromosome. Furthermore, results including data with Southern blot analysis alone (germline vs rearranged) did not differ from those observed with cytogenetic analysis (data not shown). This is the first report of a large series of DLBCL suggesting that mRNA BCL-6 expression is not necessarily correlated to the translocation of the gene. Despite the fact that in vitro experiments support the commonly accepted hypothesis that translocation of the gene alters BCL-6 expression by promoter substitutions, 21, 22 some data have shown a lack of correlation between the two processes. Previous studies in limited series of DLBCL, using immunochemistry, also did not find a correlation between expression of the protein and rearrangement of the gene. 4, 41, 42, 49, 50 Although immunochemistry is not sufficiently sensitive to show a weak difference in expression, a microarray approach, with data suggesting a good correlation with TaqMan method, 44 also failed to find a link between expression and rearrangement of the gene in DLBCL. 43 Our method reveals a link between expression and histology of lymphoma, but we can not, however, rule out that the sensitivity of our method is insufficient. It is possible that translocation induces an unstable fusion transcript with a shorter half-life than the normal transcript or that untranslocated alleles are expressed in the two groups, hiding expression of the translocated gene. Nevertheless, among the 3q27 rearranged group (Figure 2b ) expression is not homogeneous, and indicates that translocation can be implicated in some cases, but also that up-regulation of the gene may not remain constant during lymphomagenesis. These data suggest implication of alternative or additional deregulation pathways, most likely modification of regulator elements of the first intron, 51 able to interfere with BCL-6 expression controlled by the translocation. It is interesting to point out that only one study identified BCL-6 rearrangement as a prognosis factor in DLBCL, 52 whereas several other studies failed to confer to it a predictive value in DLBCL or FCL. 9, [53] [54] [55] Conversely, Lossos and colleagues 29 showed that BCL-6 expression strongly predicts survival in patients with DLBCL, also suggesting the independence between rearrangement and expression. Interestingly, mutations of a short hot spot, located into the first BCL-6 intron, have been recently associated with an increase of BCL-6 expression and an increase overall survival in DLBCL. 32 These studies and the results obtained by Vitolo and colleagues, 56 which confer a prognostic value to BCL-6 mutations, suggest that BCL-6 expression and somatic mutations may be crucial during DLBCL development. Whether somatic mutations and BCL-6 expression can be directly implicated during the oncogenic process or simply Leukemia related to the germinal center phenotype remains to be determined.
Additionally, as it was observed that the rearranged partner gene with BCL-6 could have a prognostic value, 57 we compared BCL-6 expression as regards to the rearranged partner gene and did not find any difference between the Ig and nonIg translocated partner groups. A study in cell lines involving different partners, is necessary to assess the accurate implication of each partner in BCL-6 expression.
Recent data and our present work allow to reconsider BCL-6 gene function in lymphoma to be studied, commonly based on the BCL-2 or c-MYC genes paradigm, and qualified as proto-oncogenes. Studies have now clearly suggested that BCL-6 can promote in vivo apoptosis in different cellular models. 8, [58] [59] [60] Biallelic mutations are frequent 61 and expression of the gene is associated with a better prognosis in DLBCL. 37, 43 We also showed that translocation of the gene is not necessarily associated with an up-regulation of the gene and that FCL with cytological aggressive features (grade 3) expressed less BCL-6 than indolent FCL. All of these features are not usually observed in proto-oncogenes and contrast with the fact that BCL-6 alteration is one of the most common abnormalities in NHL, also found in some lymphoma cases as the sole karyotypic abnormality.
62 BCL-6 protein is a transcriptional repressor acting with several partners [63] [64] [65] and controls expression of a wide spectrum of target genes, 68 but it can act also as a transcriptional activator under certain conditions. 66 For that reason, BCL-6 protein activity is related to the maturation stage of tumor cells and to expression of the protein partners, and most likely participates in a different way in FCL or DLBCL development. BCL-6 protein may act in a two-step process during FCL oncogenesis. As the first step, BCL-6 in a GC cell, usually t(14;18)-positive and lacking BCL-6 rearrangement, is highly expressed, blocks the B-cell terminal differentiation, and may act in synergy with the anti-apoptotic BCL-2 protein, facilitating emergence of a lymphoma with a follicle growth pattern. As the second step, BCL-6 gene (and/or associated partners) can be down-regulated, may be by mutations of the first intron regulatory elements acquired during GC transit, losing its pro-apoptotic activity and leading to a more aggressive disease similar to DLBCL.
In conclusion, we showed that BCL-6 expression in lymphoma is largely independent of chromosome 3q27 rearrangement and is more related to the histological subtype. The clinical implication and prognostic value of our results should be assessed in an homogenous and unselected group of patients with FCL and DLBCL at the time of diagnosis. Our method also provides a good approach to explore alternative pathways, unrelated to the sole translocation mechanism, and most likely implicated in the deregulation of the gene.
